Skip to main content
Premium Trial:

Request an Annual Quote

Wyeth-Ayerst Invests $2 Million in ArQule

Premium

MEDFORD, Mass.--Wyeth-Ayerst Pharmaceuticals, a division of American Home Products based in Radnor, Pa., has made a $2 million equity investment in ArQule, a combinatorial chemistry company here. ArQule will collaborate in the discovery and optimization of drug candidates for a minimum of 15 of Wyeth's selected pharmaceutical targets. Wyeth will pay ArQule approximately $28 million, including the $2 million equity investment, as well as additional fees and milestone payments, as compounds enter clinical trials, ArQule reported. In addition, ArQule will be entitled to royalties from sales of any products emanating from this collaboration.

Filed under

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.